Načítá se...
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective...
Uloženo v:
| Vydáno v: | Genes (Basel) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8228461/ https://ncbi.nlm.nih.gov/pubmed/34200676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/genes12060899 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|